Already on Wednesday afternoon, Denmark's largest pharmaceutical company, Novo Nordisk, has disclosed the figures for the second quarter of the year, while the company also upgrades its guidance for the firm's revenue and operating result.
Now, Novo Nordisk expects revenue growth in the range of 10-13 percent after currency adjustments, up against the previous 6-10 percent. As to the operating profit, the firm predicts this will grow between 9-12 percent after currency adjustments, compared with the previous 5-9 percent.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.